Online inquiry

IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4164MR)

This product GTTS-WQ4164MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets LAG3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_002286.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3902
UniProt ID P18627
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4164MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14886MR IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA SGN-LIV1A
GTTS-WQ4133MR IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BI-505
GTTS-WQ9178MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA IMGN-529
GTTS-WQ7408MR IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GA201
GTTS-WQ3317MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ASN-100
GTTS-WQ12231MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ13592MR IVTScrip™ mRNA-Anti-IL13, QAX-576(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA QAX-576
GTTS-WQ1190MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABP 980
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW